You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriamcinolone
Accession NumberDB00620  (APRD00422)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)
Structure
Thumb
Synonyms
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
Fluoxyprednisolone
Tiamcinolonum
Triamcinolona
Triamcinolonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AllernazeSpray, metered.5 mg/mLNasalLupin Pharmaceuticals2011-02-01Not applicableUs
Aristocort - Syr Orl 0.4mg/mlSyrup.4 mgOralGlades, Division Of Stiefel Canada Inc.1996-10-101997-08-05Canada
Aristocort - Tab 4mgTablet4 mgOralGlades, Division Of Stiefel Canada Inc.1998-05-112004-01-27Canada
Aristocort CCream0.5 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-10-21Not applicableCanada
Aristocort C Crm 0.5%Cream5 mgTopicalLederle Cyanamid Canada Inc.1965-12-311997-08-14Canada
Aristocort D - Crm Top 0.025%Cream.025 %TopicalGlades, Division Of Stiefel Canada Inc.1996-10-101998-07-09Canada
Aristocort D Crm 0.025%Cream.25 mgTopicalLederle Cyanamid Canada Inc.1974-12-311997-01-29Canada
Aristocort Forte - Liq Ia Im Isy 40mg/mlLiquid40 mgIntra-articular; Intramuscular; IntrasynovialGlades, Division Of Stiefel Canada Inc.1996-12-062000-12-04Canada
Aristocort Forte Inj 40mg/mlLiquid40 mgIntra-articular; Intramuscular; IntrasynovialLederle Cyanamid Canada Inc.1962-12-311997-01-29Canada
Aristocort Inj Intralesional 25mg/mlLiquid25 mgIntra-articular; Intradermal; IntramuscularLederle Cyanamid Canada Inc.1962-12-311997-01-29Canada
Aristocort Inj Intralesional-25mg/mlLiquid25 mgIntra-articular; Intradermal; IntramuscularGlades, Division Of Stiefel Canada Inc.1997-01-202001-08-21Canada
Aristocort ROintment0.1 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-04-14Not applicableCanada
Aristocort RCream0.1 %TopicalValeant Canada Lp Valeant Canada S.E.C.1996-10-10Not applicableCanada
Aristocort ROintment0.1 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-04-14Not applicableCanada
Aristocort R Crm 0.1%Cream1 mgTopicalLederle Cyanamid Canada Inc.1965-12-311997-01-29Canada
Aristocort R Ont 0.1%Ointment.1 %TopicalLederle Cyanamid Canada Inc.1969-12-311997-08-14Canada
Aristocort Syr 2mg/5mlSyrup2 mgOralLederle Cyanamid Canada Inc.1960-12-311997-01-29Canada
Aristocort Tab 2mgTablet2 mgOralLederle Cyanamid Canada Inc.1958-12-311997-01-29Canada
Aristocort Tab 4mgTablet4 mgOralLederle Cyanamid Canada Inc.1958-12-311997-08-14Canada
Aristocort-tab 2mgTablet2 mgOralGlades, Division Of Stiefel Canada Inc.1997-01-202001-10-10Canada
AristospanInjection, suspension5 mg/mLIntralesional; ParenteralSandoz Inc1969-07-29Not applicableUs
AristospanInjection, suspension20 mg/mLIntra-articular; ParenteralSandoz Inc1969-07-29Not applicableUs
AristospanSuspension20 mgIntra-articularValeo Pharma Inc1997-01-20Not applicableCanada
Aristospan Sus 20mg/mlSuspension20 mgIntra-articularLederle Cyanamid Canada Inc.1975-12-311997-01-29Canada
AzmacortAerosol, metered200 mcgRespiratory (inhalation)Aventis Pharma Inc1989-12-312003-07-22Canada
KenalogAerosol, spray.147 mg/gTopicalRanbaxy Laboratories Inc.2009-05-19Not applicableUs
Kenalog Cream 0.1%Cream1 mgTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1959-12-312006-02-10Canada
Kenalog In Orabase 0.1%Paste1 mgDentalBristol Myers Squibb Canada1961-12-312008-09-04Canada
Kenalog Ointment 0.1%Ointment1 mgTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1958-12-312004-08-05Canada
Kenalog Ont 0.1%Ointment1 mgTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1958-12-311997-08-14Canada
Kenalog-10Injection, suspension10 mg/mLIntra-articular; IntralesionalDispensing Solutions, Inc.2009-06-01Not applicableUs
Kenalog-10Injection, suspension10 mg/mLIntra-articular; IntralesionalE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Kenalog-10Injection, suspension10 mg/mLIntra-articular; IntralesionalPhysicians Total Care, Inc.2000-05-02Not applicableUs
Kenalog-10Injection, suspension10 mg/mLIntra-articular; IntralesionalA S Medication Solutions2009-06-01Not applicableUs
Kenalog-10 Injection 10mg/mlSuspension10 mgIntra-articular; Intrabursal; Intradermal; IntrasynovialBristol Myers Squibb Canada1966-12-31Not applicableCanada
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularDispensing Solutions, Inc.2009-06-01Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Kenalog-40Injection, suspension40 mg/1IntramuscularREMEDYREPACK INC.2013-04-11Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularA S Medication Solutions2009-06-01Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularRebel Distributors2009-06-01Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntramuscularREMEDYREPACK INC.2013-09-24Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularA S Medication Solutions2009-06-01Not applicableUs
Kenalog-40Injection, suspension40 mg/1IntramuscularREMEDYREPACK INC.2013-04-11Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularProficient Rx LP2009-06-01Not applicableUs
Kenalog-40Injection, suspension40 mg/mLIntra-articular; IntramuscularPhysicians Total Care, Inc.1996-06-11Not applicableUs
Kenalog-40 Injection 40mg/mlSuspension40 mgIntra-articular; IntramuscularBristol Myers Squibb Canada1973-12-31Not applicableCanada
NasacortAerosol, metered100 mcgNasalSanofi Aventis Canada Inc1992-12-312012-10-10Canada
Nasacort AQSpray, metered55 mcgNasalSanofi Aventis Canada Inc1996-12-31Not applicableCanada
Nasacort AQSpray, metered55 ug/1NasalSanofi Aventis U.S. Llc1996-05-20Not applicableUs
Oracort Dental Paste 0.1%Paste.1 %DentalTaro Pharmaceuticals Inc1992-12-31Not applicableCanada
Readysharp TriamcinoloneInjection, solution40 mg/mLIntra-articular; IntramuscularTerrain Pharmaceuticals2009-06-01Not applicableUs
Scheinpharm Triamcine-A Inject.sus-40mg/mlSuspension40 mgIntramuscularSchein Pharmaceutical Canada Inc.1996-09-202004-07-26Canada
Triaderm Crm 0.025%Cream.025 %TopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Triaderm Crm 0.1%Cream0.1 %TopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Triaderm Ont 0.025%Ointment0.25 mgTopicalTaro Pharmaceuticals Inc1979-12-312001-08-21Canada
Triaderm Ont 0.1%Ointment1 mgTopicalTaro Pharmaceuticals Inc1988-12-31Not applicableCanada
Triamcinolone AcetonideCream.25 mg/gTopicalRenaissance Pharma, Inc.2016-10-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalRenaissance Pharma, Inc.2016-10-01Not applicableUs
Triamcinolone AcetonideSpray, metered55 ug/1NasalWinthrop U.S.2011-06-15Not applicableUs
Triamcinolone Acetonide Injectable Suspension USPSuspension10 mgIntra-articular; Intrabursal; Intradermal; IntrasynovialSandoz Canada Incorporated1997-03-26Not applicableCanada
Triamcinolone Acetonide Injectable Suspension USPSuspension40 mgIntra-articular; Intrabursal; IntramuscularSandoz Canada Incorporated1997-03-26Not applicableCanada
Triamcinolone Acetonide SuspensionSuspension40 mgIntra-articular; IntramuscularSterimax Inc1993-12-31Not applicableCanada
Triamcinolone Diacetate Sus 40mg/mlSuspension40 mgIntralesionalTaro Pharmaceuticals Inc1980-12-312001-08-21Canada
Triamcinolone Diacetate SuspensionSuspension40 mgIntra-articular; Intradermal; Intralesional; IntramuscularSterimax Inc1992-11-19Not applicableCanada
TriesenceSuspension40 mgIntravitrealAlcon Canada Inc2012-08-22Not applicableCanada
TriesenceInjection, suspension40 mg/mLOphthalmicAlcon Laboratories, Inc.2007-11-15Not applicableUs
Triloan II SuikInjection, solution40 mg/mLIntra-articular; IntramuscularAsclemed Usa, Inc.2009-06-01Not applicableUs
Triloan SuikInjection, solution40 mg/mLIntra-articular; IntramuscularAsclemed Usa, Inc.2009-06-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-triamcinolone AQSpray, metered55 mcgNasalApotex Inc2016-06-15Not applicableCanada
Dermacinrx Silazone PakKitPure Tek Corporation2015-12-10Not applicableUs
Dermacinrx TrizapakKitPure Tek Corporation2016-08-02Not applicableUs
Dermasorb Ta Complete KitKitCrown Laboratories2013-11-14Not applicableUs
DermazoneKitShoreline Pharmaceuticals, Inc.2016-04-20Not applicableUs
OralonePaste1 mg/gDentalTaro Pharmaceuticals U.S.A., Inc.1986-10-01Not applicableUs
Pediaderm TaCream1 mg/gTopicalArbor Pharmaceuticals, Inc.2010-09-01Not applicableUs
Pediaderm TaKitArbor Pharmaceuticals, Inc.2011-01-01Not applicableUs
Silazone-IIKitPure Tek Corporation2016-01-20Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalPhysicians Total Care, Inc.2006-09-18Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalClinical Solutions Wholesale2012-04-01Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions1978-03-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalGlenmark Pharmaceuticals Inc., Usa2016-08-05Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalAidarex Pharmaceuticals LLC2006-06-09Not applicableUs
Triamcinolone AcetonideOintment5 mg/gTopicalProficient Rx LP2006-11-10Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalQualitest Pharmaceuticals2006-12-13Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1978-03-09Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1978-03-09Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalA S Medication Solutions Llc2006-05-12Not applicableUs
Triamcinolone AcetonideOintment5 mg/gTopicalPerrigo New York Inc2006-11-10Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalLiberty Pharmaceuticals, Inc.2012-04-01Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalTeligent Pharma, Inc.2016-07-08Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions2006-06-09Not applicableUs
Triamcinolone AcetonidePaste1 mg/gDentalTaro Pharmaceuticals U.S.A., Inc.1986-10-01Not applicableUs
Triamcinolone AcetonideLotion.25 mg/mLTopicalVersa Pharm Incorporated2013-05-21Not applicableUs
Triamcinolone AcetonideSpray, metered55 ug/1NasalTeva Pharmaceuticals USA Inc2011-06-152016-06-30Us
Triamcinolone AcetonideCream5 mg/gTopicalRebel Distributors Corp1978-03-09Not applicableUs
Triamcinolone AcetonideAerosol, spray.147 mg/gTopicalPerrigo New York Inc2015-04-17Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1978-02-14Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalLake Erie Medical DBA Quality Care Products LLC2012-04-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalPreferred Pharmaceuticals, Inc2012-02-14Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions1978-03-09Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions2006-10-092016-10-21Us
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions Llc1978-03-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalAscend Laboratories, LLC2012-04-01Not applicableUs
Triamcinolone AcetonideInjection, suspension40 mg/mLIntra-articular; IntramuscularSandoz Inc2009-05-27Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalArbor Pharmaceuticals Inc.1997-11-26Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalPhysicians Total Care, Inc.1995-02-22Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalPerrigo New York Inc2006-09-28Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions2012-04-01Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalREMEDYREPACK INC.2016-07-27Not applicableUs
Triamcinolone AcetonideCream1 mg/1TopicalREMEDYREPACK INC.2013-04-12Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalProficient Rx LP2012-04-01Not applicableUs
Triamcinolone AcetonidePaste1 mg/gDentalPhysicians Total Care, Inc.2003-09-03Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalREMEDYREPACK INC.2014-09-10Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalA S Medication Solutions1978-03-09Not applicableUs
Triamcinolone AcetonideOintment5 mg/gTopicalGlenmark Pharmaceuticals Inc., Usa2016-07-22Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions Llc1978-03-09Not applicableUs
Triamcinolone AcetonidePaste1 mg/gTopicalRising Pharmaceuticals, Inc.2010-07-07Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalG&W Laboratories, Inc.2015-09-10Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1997-11-26Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1978-03-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalCentral Texas Community Health Centers2006-09-28Not applicableUs
Triamcinolone AcetonidePaste1 mg/gTopicalA S Medication Solutions Llc2010-07-07Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalPerrigo New York Inc2006-05-12Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions2012-04-01Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalTeligent Pharma, Inc.2016-05-13Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions2006-06-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1997-11-26Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalVersa Pharm Incorporated2013-05-21Not applicableUs
Triamcinolone AcetonideLotion.25 mg/mLTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2003-04-21Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalRebel Distributors Corp2009-10-07Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalA S Medication Solutions Llc1978-02-14Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalAscend Laboratories, LLC2012-04-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalSTAT RX LLC USA1981-04-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalMedsource Pharmaceuticals2012-04-01Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalQualitest Pharmaceuticals2006-06-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalG&W Laboratories, Inc.2015-04-14Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions2012-04-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions2006-09-28Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalREMEDYREPACK INC.2013-12-03Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalProficient Rx LP1978-03-09Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalPhysicians Total Care, Inc.1994-11-22Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalPerrigo New York Inc2006-05-17Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions1978-03-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalREMEDYREPACK INC.2016-09-21Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalRebel Distributors Corp2009-10-07Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1978-03-09Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalPhysicians Total Care, Inc.2005-01-26Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalA S Medication Solutions2006-05-12Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalLiberty Pharmaceuticals, Inc.2012-04-01Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalA S Medication Solutions Llc1978-02-14Not applicableUs
Triamcinolone AcetonideSpray, metered55 ug/1NasalMed Vantx, Inc.2011-04-06Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalG&W Laboratories, Inc.2015-09-10Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalRebel Distributors Corp2009-10-07Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalUnit Dose Services2012-04-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions Llc1978-03-09Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalPerrigo New York Inc2006-08-04Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalA S Medication Solutions1978-02-14Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalA S Medication Solutions1994-09-30Not applicableUs
Triamcinolone AcetonideOintment5 mg/gTopicalREMEDYREPACK INC.2015-03-02Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2003-04-21Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions Llc1978-03-09Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalAscend Laboratories, LLC2012-04-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalRebel Distributors Corp1978-03-09Not applicableUs
Triamcinolone AcetonideOintment.5 mg/gTopicalCarolina Medical Products Company1995-03-23Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalQualitest Pharmaceuticals2006-06-09Not applicableUs
Triamcinolone AcetonideLotion.25 mg/mLTopicalMorton Grove Pharmaceuticals, Inc.1985-04-01Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalG&W Laboratories, Inc.2015-04-14Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions1997-11-26Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalA S Medication Solutions2006-05-17Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalH.J. Harkins Company, Inc.2006-09-28Not applicableUs
Triamcinolone AcetonideCream.025 mg/gTopicalProficient Rx LP1978-03-09Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalPhysicians Total Care, Inc.1994-11-22Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1994-09-30Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalA S Medication Solutions1978-02-14Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalNu Care Pharmaceuticals, Inc.2012-04-01Not applicableUs
Triamcinolone AcetonidePaste1 mg/gTopicalAv Kare, Inc.2012-03-28Not applicableUs
Triamcinolone AcetonideOintment.25 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1978-02-14Not applicableUs
Triamcinolone AcetonideSpray, metered55 ug/1NasalPhysicians Total Care, Inc.2011-09-14Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalPreferred Pharmaceuticals, Inc.2008-06-10Not applicableUs
Triamcinolone AcetonidePaste1 mg/gTopicalA S Medication Solutions2010-07-07Not applicableUs
Triamcinolone AcetonideOintment1 mg/gTopicalA S Medication Solutions2006-08-04Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions Llc1978-03-09Not applicableUs
Triamcinolone AcetonideInjection, suspension10 mg/mLIntra-articular; Intrabursal; Intradermal; IntralesionalSandoz Inc2009-05-27Not applicableUs
Triamcinolone AcetonidePaste1 mg/gTopicalRebel Distributors Corp2010-07-07Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalUnit Dose Services1978-03-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalPhysicians Total Care, Inc.1995-02-22Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalPerrigo New York Inc2006-10-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions1978-03-09Not applicableUs
Triamcinolone AcetonidePaste1 mg/gDentalVersa Pharm Incorporated2016-08-19Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalA S Medication Solutions2012-04-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalREMEDYREPACK INC.2013-06-13Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalDIRECT RX2014-01-01Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalA S Medication Solutions2012-04-01Not applicableUs
Triamcinolone AcetonideCream5 mg/gTopicalA S Medication Solutions Llc1978-03-09Not applicableUs
Triamcinolone AcetonideOintment5 mg/gTopicalDispensing Solutions, Inc.2006-11-10Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalRebel Distributors Corp1978-03-09Not applicableUs
Triamcinolone AcetonideCream1 mg/gTopicalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-20Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalG&W Laboratories, Inc.2015-04-01Not applicableUs
Triamcinolone AcetonideLotion1 mg/mLTopicalMorton Grove Pharmaceuticals, Inc.1985-04-03Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalLiberty Pharmaceuticals, Inc.2012-04-01Not applicableUs
Triamcinolone AcetonideLotion.25 mg/mLTopicalTeligent Pharma, Inc.2016-07-08Not applicableUs
TrianexOintment.5 mg/gTopicalUpsher Smith Laboratories, Inc.2011-05-27Not applicableUs
Trianex 0.05%Ointment.5 mg/gTopicalPromius Pharma, LLC2015-02-18Not applicableUs
TridermCream.25 mg/gTopicalCrown Laboratories1984-03-19Not applicableUs
TridermCream1 mg/gTopicalCrown Laboratories1984-03-19Not applicableUs
TridermCream5 mg/gTopicalCrown Laboratories1984-03-19Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour Nasal AllergySpray, suspension55 ug/1NasalKroger Company2016-04-10Not applicableUs
Allergy NasalSpray, suspension55 ug/1NasalWalgreen Company2016-04-10Not applicableUs
Childrens Nasacort Allergy 24hrSpray, metered55 ug/1NasalChattem, Inc.2015-07-01Not applicableUs
Equate Nasal AllergySpray, metered55 ug/1NasalWal Mart Stores Inc2016-04-17Not applicableUs
Good Neighbor Pharmacy 24 Hour Nasal AllergySpray, metered55 ug/1NasalAmerisource Bergen2016-10-24Not applicableUs
Nasacort Allergy 24hrSpray, metered55 mcgNasalSanofi Aventis Canada Inc2015-07-06Not applicableCanada
Nasacort Allergy 24hrSpray, metered55 ug/1NasalChattem, Inc.2014-02-03Not applicableUs
Nasal AllergySpray, suspension55 ug/1NasalCVS Pharmacy2016-04-10Not applicableUs
Nasal Allergy 24 HourSpray, metered55 ug/1NasalGeiss, Destin & Dunn Inc.2015-06-19Not applicableUs
Nasal Spray Allergy 24hrSpray, metered55 mcgNasalApotex IncNot applicableNot applicableCanada
Signature Care Nasal AllergySpray, metered55 ug/1NasalSafeway2016-11-07Not applicableUs
Triamcinolone Acetonide GlucocorticoidSpray, metered55 ug/1NasalPerrigo New York Inc2016-08-17Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AristocortNot Available
DelphicortNot Available
FlutexNot Available
KenacortNot Available
Omcilon-ANot Available
OracortNot Available
Tri-NasalNot Available
TriacetNot Available
TriacortNot Available
TriadermNot Available
TricortoneNot Available
TriloneNot Available
TristojectNot Available
Brand mixtures
NameLabellerIngredients
Aristoform R Crm 0.1%Lederle Cyanamid Canada Inc.
Kenacomb CreamWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb Mild CreamWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb Mild OintmentWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb OintmentWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb OntSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Mecomb Crm 0.1%Medic Laboratory LtÉe
Nystatin and TriamcinoloneSTAT RX LLC USA
Nystatin and Triamcinolone AcetonideE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
Physician Ez Use Joint Tunnel and Trigger KitAsclemed Usa, Inc.
Ratio-triacombTeva Canada Limited
Readysharp-KTerrain Pharmaceuticals
Theraderm CreamBimeda Mtc Animal Health Inc
Viaderm Kc CrmTaro Pharmaceuticals Inc
Viaderm Kc OntTaro Pharmaceuticals Inc
Salts
Name/CASStructureProperties
Triamcinolone acetonide
ThumbNot applicableDBSALT000860
Triamcinolone diacetate
ThumbNot applicableDBSALT000859
Triamcinolone hexacetonide
ThumbNot applicableDBSALT000861
Categories
UNII1ZK20VI6TY
CAS number124-94-7
WeightAverage: 394.4339
Monoisotopic: 394.179166801
Chemical FormulaC21H27FO6
InChI KeyGFNANZIMVAIWHM-OBYCQNJPSA-N
InChI
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor the treatment of perennial and seasonal allergic rhinitis.
Structured Indications
PharmacodynamicsTriamcinolone and its derivatives are synthetic glucocorticoids that are used for their antiinflammatory or immunosuppressive properties.
Mechanism of actionThe antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionRapid absorption following oral administration
Volume of distributionNot Available
Protein binding68%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life88 minutes
ClearanceNot Available
ToxicityLD50=>500mg/kg (in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with 1,10-Phenanthroline.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Triamcinolone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Triamcinolone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triamcinolone.Withdrawn
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Triamcinolone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Triamcinolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Triamcinolone.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Triamcinolone.Experimental
AldesleukinTriamcinolone may decrease the antineoplastic activities of Aldesleukin.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triamcinolone.Approved
ALT-110The risk or severity of adverse effects can be increased when Triamcinolone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Triamcinolone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Triamcinolone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Triamcinolone.Approved
AmiodaroneThe metabolism of Triamcinolone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BTriamcinolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Triamcinolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Triamcinolone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Triamcinolone.Approved, Investigational
AprepitantThe serum concentration of Triamcinolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Triamcinolone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Triamcinolone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Triamcinolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triamcinolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triamcinolone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Triamcinolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Triamcinolone.Approved, Investigational
BazedoxifeneThe serum concentration of Triamcinolone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Triamcinolone.Investigational
BendroflumethiazideTriamcinolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Triamcinolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Triamcinolone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Triamcinolone.Investigational
BexaroteneThe serum concentration of Triamcinolone can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Triamcinolone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Triamcinolone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Triamcinolone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Triamcinolone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Triamcinolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Triamcinolone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Triamcinolone.Withdrawn
BumetanideTriamcinolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Triamcinolone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Triamcinolone can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triamcinolone.Approved
CarbamazepineThe metabolism of Triamcinolone can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Triamcinolone.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triamcinolone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Triamcinolone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Triamcinolone.Approved, Investigational
CeritinibThe serum concentration of Triamcinolone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Triamcinolone.Approved, Vet Approved
ChlorothiazideTriamcinolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Triamcinolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triamcinolone.Approved
ChlorthalidoneTriamcinolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triamcinolone.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Triamcinolone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Triamcinolone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Triamcinolone.Approved
ClotrimazoleThe metabolism of Triamcinolone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Triamcinolone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Triamcinolone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Triamcinolone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Triamcinolone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Triamcinolone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Triamcinolone.Investigational
CyclosporineThe metabolism of Triamcinolone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Triamcinolone.Investigational
DabrafenibThe serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Triamcinolone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Triamcinolone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Triamcinolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Triamcinolone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Triamcinolone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Triamcinolone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Triamcinolone.Investigational
DexamethasoneThe serum concentration of Triamcinolone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Triamcinolone.Approved, Vet Approved
DienestrolThe serum concentration of Triamcinolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Triamcinolone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triamcinolone.Approved
DihydroergotamineThe metabolism of Triamcinolone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneTriamcinolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Triamcinolone can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Triamcinolone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Triamcinolone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Triamcinolone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triamcinolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Triamcinolone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Triamcinolone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Triamcinolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Triamcinolone can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triamcinolone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Triamcinolone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Triamcinolone.Approved
ErythromycinThe metabolism of Triamcinolone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Triamcinolone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Triamcinolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Triamcinolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Triamcinolone can be increased when it is combined with Estrone.Approved
Etacrynic acidTriamcinolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Triamcinolone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Triamcinolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Triamcinolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Triamcinolone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Triamcinolone.Approved, Investigational
EtravirineThe serum concentration of Triamcinolone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Triamcinolone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Triamcinolone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Triamcinolone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Triamcinolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Triamcinolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fenthion.Vet Approved
FingolimodTriamcinolone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Triamcinolone.Approved, Withdrawn
FluconazoleThe metabolism of Triamcinolone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Triamcinolone.Vet Approved
FluoxymesteroneTriamcinolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Triamcinolone.Approved, Investigational
FluvoxamineThe metabolism of Triamcinolone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Triamcinolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Triamcinolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Triamcinolone can be increased when combined with Fosphenytoin.Approved
FurosemideTriamcinolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Triamcinolone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Triamcinolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Triamcinolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Triamcinolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Triamcinolone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Triamcinolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Triamcinolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triamcinolone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triamcinolone.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Triamcinolone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Triamcinolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Triamcinolone.Investigational
HexestrolThe serum concentration of Triamcinolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Triamcinolone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Triamcinolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.Approved, Investigational
HydrochlorothiazideTriamcinolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTriamcinolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Triamcinolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Triamcinolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Triamcinolone.Approved
IdelalisibThe serum concentration of Triamcinolone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Triamcinolone can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Triamcinolone.Approved
IndapamideTriamcinolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Triamcinolone can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Triamcinolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Triamcinolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Triamcinolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Triamcinolone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Triamcinolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Triamcinolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triamcinolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Triamcinolone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triamcinolone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triamcinolone.Approved
IsavuconazoniumThe metabolism of Triamcinolone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Triamcinolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Triamcinolone.Withdrawn
IsradipineThe metabolism of Triamcinolone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Triamcinolone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Triamcinolone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Triamcinolone.Experimental
KetoconazoleThe metabolism of Triamcinolone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Triamcinolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Triamcinolone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Triamcinolone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Triamcinolone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Triamcinolone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Triamcinolone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Triamcinolone.Approved
LovastatinThe metabolism of Triamcinolone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Triamcinolone.Approved
LuliconazoleThe serum concentration of Triamcinolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Triamcinolone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Triamcinolone.Approved, Investigational
MagaldrateThe bioavailability of Triamcinolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Triamcinolone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Triamcinolone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Triamcinolone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triamcinolone.Approved
Magnesium TrisilicateThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triamcinolone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Triamcinolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Triamcinolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Triamcinolone.Approved
MestranolThe serum concentration of Triamcinolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Triamcinolone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.Approved
MethallenestrilThe serum concentration of Triamcinolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideTriamcinolone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneTriamcinolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneTriamcinolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Triamcinolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Triamcinolone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Triamcinolone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Triamcinolone.Approved, Investigational
MitotaneThe serum concentration of Triamcinolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Triamcinolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Triamcinolone.Investigational
ModafinilThe serum concentration of Triamcinolone can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Triamcinolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Triamcinolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Triamcinolone.Investigational
NafcillinThe serum concentration of Triamcinolone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Triamcinolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Triamcinolone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Triamcinolone.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Triamcinolone.Investigational
NefazodoneThe metabolism of Triamcinolone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Triamcinolone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Triamcinolone.Approved
NetupitantThe serum concentration of Triamcinolone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Triamcinolone can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Triamcinolone.Approved
NilotinibThe metabolism of Triamcinolone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Triamcinolone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Triamcinolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Triamcinolone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triamcinolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Triamcinolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Triamcinolone.Vet Approved
OsimertinibThe serum concentration of Triamcinolone can be increased when it is combined with Osimertinib.Approved
OxandroloneTriamcinolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Triamcinolone.Approved
OxymetholoneTriamcinolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triamcinolone.Withdrawn
PalbociclibThe serum concentration of Triamcinolone can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Triamcinolone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Triamcinolone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Triamcinolone.Approved, Withdrawn
PhenobarbitalThe metabolism of Triamcinolone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Triamcinolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Triamcinolone.Approved, Vet Approved
PhenytoinThe metabolism of Triamcinolone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triamcinolone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triamcinolone.Approved, Investigational
PiretanideTriamcinolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triamcinolone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triamcinolone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Triamcinolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideTriamcinolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Triamcinolone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Triamcinolone.Approved, Investigational
PrimidoneThe metabolism of Triamcinolone can be increased when combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Triamcinolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Triamcinolone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Triamcinolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Triamcinolone can be increased when it is combined with Quinestrol.Approved
QuinethazoneTriamcinolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Triamcinolone.Approved
RanolazineThe metabolism of Triamcinolone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Triamcinolone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Triamcinolone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone.Experimental, Investigational
RifabutinThe metabolism of Triamcinolone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Triamcinolone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Triamcinolone can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Triamcinolone can be decreased when combined with Ritonavir.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Triamcinolone.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Triamcinolone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Triamcinolone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triamcinolone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Triamcinolone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triamcinolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Triamcinolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Triamcinolone.Approved
SaquinavirThe metabolism of Triamcinolone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Triamcinolone.Approved
SecoisolariciresinolThe serum concentration of Triamcinolone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triamcinolone.Approved, Investigational
SildenafilThe metabolism of Triamcinolone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Triamcinolone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Triamcinolone can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Triamcinolone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triamcinolone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Triamcinolone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Triamcinolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Triamcinolone.Investigational
St. John's WortThe serum concentration of Triamcinolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololTriamcinolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Triamcinolone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Triamcinolone.Approved
SulfisoxazoleThe metabolism of Triamcinolone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Triamcinolone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triamcinolone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Triamcinolone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Triamcinolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Triamcinolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Triamcinolone.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Triamcinolone.Approved
TelithromycinThe metabolism of Triamcinolone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Triamcinolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Triamcinolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Triamcinolone.Approved
TestosteroneTriamcinolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Triamcinolone is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Triamcinolone.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Triamcinolone.Approved
TiboloneThe serum concentration of Triamcinolone can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Triamcinolone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Triamcinolone.Investigational
TocilizumabThe serum concentration of Triamcinolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTriamcinolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triamcinolone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triamcinolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triamcinolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Triamcinolone.Approved
TorasemideTriamcinolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Triamcinolone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Triamcinolone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Trichlorfon.Vet Approved
TrichlormethiazideTriamcinolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Triamcinolone.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Triamcinolone.Withdrawn
TrovafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Triamcinolone.Investigational, Withdrawn
VenlafaxineThe metabolism of Triamcinolone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Triamcinolone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triamcinolone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Triamcinolone.Approved, Investigational
VoriconazoleThe metabolism of Triamcinolone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTriamcinolone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triamcinolone.Approved
ZeranolThe serum concentration of Triamcinolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Triamcinolone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Triamcinolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triamcinolone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Abu Alam, “Triamcinolone formulations and methods for their preparation and use.” U.S. Patent US20040186084, issued September 23, 2004.

US20040186084
General ReferencesNot Available
External Links
ATC CodesR01AD11D07CB01D07BB03S02CA04C05AA12D07AB09S01BA05H02AB08R03BA06A01AC01D07XB02
AHFS Codes
  • 52:08.08
  • 68:04.00
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (150 KB)
MSDSDownload (72.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9823
Blood Brain Barrier+0.9528
Caco-2 permeable+0.7397
P-glycoprotein substrateSubstrate0.8204
P-glycoprotein inhibitor INon-inhibitor0.8759
P-glycoprotein inhibitor IINon-inhibitor0.9725
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8858
CYP450 2D6 substrateNon-substrate0.9006
CYP450 3A4 substrateSubstrate0.7049
CYP450 1A2 substrateNon-inhibitor0.9144
CYP450 2C9 inhibitorNon-inhibitor0.8939
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.911
CYP450 3A4 inhibitorNon-inhibitor0.9007
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.942
Ames testNon AMES toxic0.8858
CarcinogenicityNon-carcinogens0.9521
BiodegradationNot ready biodegradable0.9952
Rat acute toxicity2.3369 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9562
hERG inhibition (predictor II)Inhibitor0.6125
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astellas pharma us inc
  • Bristol myers squibb co
  • Barr laboratories inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Abbott laboratories
  • Sanofi aventis us llc
  • Ivax pharmaceuticals inc
  • Apothecon inc div bristol myers squibb
  • Solvay pharmaceuticals
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Altana inc
  • Ambix laboratories div organics corp america
  • G and w laboratories inc
  • Morton grove pharmaceuticals inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals usa inc
  • Topiderm inc
  • Vintage pharmaceuticals llc
  • Del ray laboratories inc
  • Savage laboratories inc div altana inc
  • Parnell pharmaceuticals inc
  • Sandoz canada inc
  • Allergan inc
  • Alcon inc
  • Bristol myers squibb co pharmaceutical research institute
  • Wockhardt eu operations (swiss) ag
  • Carolina medical products co
  • Lyne laboratories inc
  • Lupin atlantis holding sa switzerland
  • Ranbaxy laboratories inc
  • Akorn inc
Packagers
Dosage forms
FormRouteStrength
Spray, suspensionNasal55 ug/1
Spray, meteredNasal.5 mg/mL
SyrupOral.4 mg
CreamTopical0.5 %
CreamTopical5 mg
CreamTopical.25 mg
LiquidIntra-articular; Intramuscular; Intrasynovial40 mg
LiquidIntra-articular; Intradermal; Intramuscular25 mg
OintmentTopical0.1 %
CreamTopical1 mg
OintmentTopical.1 %
SyrupOral2 mg
TabletOral2 mg
TabletOral4 mg
Injection, suspensionIntra-articular; Parenteral20 mg/mL
Injection, suspensionIntralesional; Parenteral5 mg/mL
SuspensionIntra-articular20 mg
Aerosol, meteredRespiratory (inhalation)200 mcg
Kit
Aerosol, sprayTopical.147 mg/g
PasteDental1 mg
Injection, suspensionIntra-articular; Intralesional10 mg/mL
SuspensionIntra-articular; Intrabursal; Intradermal; Intrasynovial10 mg
Injection, suspensionIntra-articular; Intramuscular40 mg/mL
Injection, suspensionIntramuscular40 mg/1
Injection, suspensionIntramuscular40 mg/mL
SuspensionIntra-articular; Intramuscular40 mg
Aerosol, meteredNasal100 mcg
Spray, meteredNasal55 ug/1
Spray, meteredNasal55 mcg
CreamTopical
OintmentTopical
PasteDental.1 %
Kit
KitInfiltration; Intra-articular; Intramuscular; Respiratory (inhalation); Topical
KitEpidural; Infiltration; Intra-articular; Intramuscular; Topical
SuspensionIntramuscular40 mg
CreamTopical.025 %
CreamTopical0.1 %
OintmentTopical0.25 mg
OintmentTopical1 mg
CreamTopical.025 mg/g
CreamTopical1 mg/1
Injection, suspensionIntra-articular; Intrabursal; Intradermal; Intralesional10 mg/mL
LotionTopical.25 mg/mL
LotionTopical1 mg/mL
OintmentTopical.25 mg/g
OintmentTopical1 mg/g
OintmentTopical5 mg/g
PasteDental1 mg/g
PasteTopical1 mg/g
SuspensionIntra-articular; Intrabursal; Intramuscular40 mg
SuspensionIntralesional40 mg
SuspensionIntra-articular; Intradermal; Intralesional; Intramuscular40 mg
OintmentTopical.5 mg/g
CreamTopical.25 mg/g
CreamTopical1 mg/g
CreamTopical5 mg/g
Injection, suspensionOphthalmic40 mg/mL
SuspensionIntravitreal40 mg
Injection, solutionIntra-articular; Intramuscular40 mg/mL
Prices
Unit descriptionCostUnit
Triesence 40 mg/ml vial148.8USD ml
Kenalog Aerosol 63 gm Can118.99USD can
Nasacort AQ 55 mcg/act Aerosol (Nasal Spray)118.74USD inhaler
Triamcinolone Acetonide 0.1% Paste 5 gm Tube71.7USD tube
Kenalog 0.5% Cream 20 gm Tube54.99USD tube
Kenalog 0.1% Lotion 60ml Bottle51.99USD bottle
Kenalog 0.025% Lotion 60ml Bottle46.99USD bottle
Triamcinolone Acetonide 0.025% Lotion 60ml Bottle40.99USD bottle
Triamcinolone diacetate powder26.01USD g
Triamcinolone powder20.29USD g
Kenalog 0.1% Cream 15 gm Tube18.99USD tube
Triamcinolone Acetonide 0.1% Ointment 80 gm Tube18.99USD tube
Triamcinolone Acetonide 0.5% Ointment 15 gm Tube14.99USD tube
Aristospan 20 mg/ml vial14.19USD ml
Oralone 0.1% paste13.57USD g
Triamcinolone Acetonide 0.025% Cream 80 gm Tube12.99USD tube
Triamcinolone Acetonide 0.1% Cream 80 gm Tube12.99USD tube
Triamcinolone Acetonide 0.5% Cream 15 gm Tube12.99USD tube
Triamcinolone Acetonide 0.025% Cream 15 gm Tube11.99USD tube
Triamcinolone Acetonide 0.025% Ointment 80 gm Tube11.99USD tube
Triamcinolone Acetonide 0.1% Cream 15 gm Tube11.99USD tube
Triamcinolone Acetonide 0.1% Ointment 15 gm Tube11.99USD tube
Kenalog-40 40 mg/ml vial8.99USD ml
Triamcinolone acet 40 mg/ml sus8.42USD ml
Kenalog-40 40 mg/ml7.53USD ml
Nasacort aq nasal spray6.99USD g
Triamcinolone 0.1% paste6.4USD g
Triamcinolone Acetonide 40 mg/ml6.29USD ml
Triamcinolone Acetonide Usp 40 mg/ml5.76USD ml
Aristospan 5 mg/ml vial3.54USD ml
Kenalog-10 10 mg/ml3.24USD ml
Triamcinolone Acetonide 10 mg/ml2.71USD ml
Kenalog-10 10 mg/ml vial2.32USD ml
Triamcinolone acet 10 mg/ml sus2.18USD ml
Aristocort C 0.5 % Cream1.3USD g
Oracort 0.1 % Paste1.19USD g
Triderm 0.1% cream0.47USD g
Triamcinolone 0.5% cream0.22USD g
Aristocort R 0.1 % Cream0.15USD g
Aristocort R 0.1 % Ointment0.15USD g
Triamcinolone Acetonide 0.1% Cream0.07USD gm
Triaderm Regular 0.1 % Cream0.07USD g
Triamcinolone 0.025% cream0.06USD g
Triamcinolone Acetonide 0.1% Ointment0.05USD gm
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2268927 No2003-09-232017-07-02Canada
US5976573 No1996-07-032016-07-03Us
US6143329 No1996-07-032016-07-03Us
US6395294 No2000-01-132020-01-13Us
US7977045 No1996-07-032016-07-03Us
US8128960 No2009-12-172029-12-17Us
US8211880 No2009-03-102029-03-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 °CPhysProp
water solubility80 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.16HANSCH,C ET AL. (1995)
logS-3.69ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.847 mg/mLALOGPS
logP0.84ALOGPS
logP0.24ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)11.75ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area115.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity99.38 m3·mol-1ChemAxon
Polarizability39.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.24 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-2931000000-ee37afbf8c285181a340View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 16-hydroxysteroid
  • 11-hydroxysteroid
  • 16-alpha-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Polyol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • 1,2-diol
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58. [PubMed:19744340 ]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]
  3. Shahin V, Ludwig Y, Schafer C, Nikova D, Oberleithner H: Glucocorticoids remodel nuclear envelope structure and permeability. J Cell Sci. 2005 Jul 1;118(Pt 13):2881-9. [PubMed:15976447 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Dort K, Padia S, Wispelwey B, Moore CC: Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009 Jun 8;6:10. doi: 10.1186/1742-6405-6-10. [PubMed:19505306 ]
  2. Hagan JB, Erickson D, Singh RJ: Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5. doi: 10.1111/j.1526-4637.2010.00852.x. Epub 2010 Apr 29. [PubMed:20456080 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Schaefer EC, Stewart AA, Durgam SS, Byron CR, Stewart MC: Effects of sodium hyaluronate and triamcinolone acetonide on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. Am J Vet Res. 2009 Dec;70(12):1494-501. doi: 10.2460/ajvr.70.12.1494. [PubMed:19951121 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Ehrich M, Jortner BS, Gross WB: Types of adrenocorticoids and their effect on organophosphorus-induced delayed neuropathy in chickens. Toxicol Appl Pharmacol. 1988 Feb;92(2):214-23. [PubMed:3341034 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Groyer A, Le Bouc Y, Joab I, Radanyi C, Renoir JM, Robel P, Baulieu EE: Chick oviduct glucocorticosteroid receptor. Specific binding of the synthetic steroid RU 486 and immunological studies with antibodies to chick oviduct progesterone receptor. Eur J Biochem. 1985 Jun 3;149(2):445-51. [PubMed:3996417 ]
  4. Svec F, Harrison RW: Conditions affecting AtT-20 cell glucocorticoid uptake. Steroids. 1981 Feb;37(2):143-56. [PubMed:7222146 ]
  5. Eisen HJ: An antiserum to the rat liver glucocorticoid receptor. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3893-7. [PubMed:7001446 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:42